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S218 Poster Session Ihad early deaths and 1 had graft failure. Sustained engraftment in the
12 was observed from 1 UCB unit in all cases. The winning unit was
UCB1 in 5 (42%) and it had larger median CD8 (p5 0.009) and
thawed CD34+ cell (p5 0.006) doses infused. Median time to
achieve T cell complete donor chimerism was 30 days. Median times
to neutrophil and platelet engraftment were 20 and 46 days, respec-
tively. Median time hospitalized was 39 days. Incidence of grade 2-4
and 3-4 acute GVHD was 19% and 6%, respectively; while for
chronic GVHD it was 31% and 25% for extensive stage. 6 developed
CMV infection and 15 had other infections. There have been 2
(13%) relapses (1MDS, 1AML). 8 pts (50%) remain alive at amedian
follow-up of 15 mos (range, 5-35). Deaths included 4 infections, 1
graft failure, 1 pulmonary toxicity, 1 CNS bleed, 1 relapse (AML).
Incidence of death at 1 and 2 yrs are 45% (6% relapse, 39% non-re-
lapse) and 59% (6% relapse, 53% non-relapse), respectively. We
conclude that TBI, VP16 and ATG conditioning for MU UCBT
is effective in adult HM pts. Further strategies to enhance immune
reconstitution and prevent infection post-transplant are warranted.162
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Double cord blood transplantation (DCBT) with two partially
matched cord blood units has successfully been implemented to cir-
cumvent limitations of graft cell dose. After DCBT sustained hema-
topoiesis is derived almost exclusively from only one of the donated
units. Nonetheless, we previously observed two of six evaluable
DCBT patients having mixed donor-donor chimerism still at 28
and 45 months post-transplantation, respectively. In the present
studyweutilize flowcytometry techniques for thefirst ever deep anal-
ysis of phenotype and functionality ofCB units in patients withmixed
donor-donor chimerism. Our results suggest that the two stable CB
units are phenotypically and functionally different: One unit with
more naı¨veT cells, lower cytokine production andhigher frequencies
of NK cells, and one with higher frequencies of well differentiated
and functional lymphocytes. Additionally, in comparison to control
patients with a single prevailingCB unit, the patients with donor-do-
nor chimerism exhibit less overall cytokine production and a smaller
fraction of memory T cells. Furthermore, our results indicate that
HLA C match of donor units may partly explain the development
of a donor-donor mixed chimerism.163
SAFETY OF T-CELL REPLETE HAPLOIDENTICAL STEM CELL TRANSPLAN-
TATION USING FLUDARABINE, MELPAHALAN AND THIOTEPA CONDI-
TIONING AND HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE
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Haploidentical stem-cell transplantation (HaploSCT) has been
performed using a T-cell depleted (TCD) graft; however, a high
NRM, primarily related to infectious complications, has been the
main limitation of this approach.Wehypothesized thatT-cell replete
(TCR) haploidentical transplantation using high-dose post-trans-
plant cyclophosphamide (HDPTCy) is associated with improved
early outcomes in patients (pts) with advanced hematologic malig-
nancies treated with fludarabine, melphalan and thiotepa condition-
ing (FMT), regimen previously reported by us for TCDHaploSCT.
Methods: Eight consecutive pts with relapsed/refractory hemato-
logic malignancies (5 with AMLwith16-84%marrow blasts at trans-
plant, 2 with blast-phase and 1 chronic-phase CML) received
melphalan 140 mg/m2 I.V. on day -8, thiotepa 10 mg/m2 I.V. on
day -7, fludarabine 40 mg/m2 on days -6, -5, -4 and -3, and
HDPTCy 50 mg/kg/day on days +3 and +4 plus tacrolimus andmye-
cophenolate. Median age was 45 years (range 30-63). Three pts were
Caucasian and 5 of non-Caucasian origin (2 Asian, 2 Hispanic and 1
African-American). Donors were siblings for 3, children for 4, andparent for 1 pt, with a median of 6.5/10 allele matches (range 5-8).
All pts except one received a bone marrow graft.
Results: All 8 pts engrafted with 100% donor-derived hematopoi-
esis by PCR, and achieved remission after transplant. Median time
to neutrophil engraftment was 18 days (range 16-40) and platelet
engraftment 29 days (range 15-35, N5 6). Two patients with
anti-HLA-antibodies engrafted after 29 and 40 days, significantly
longer than the rest, 16-19 days, p\0.001). Two pts experienced
grade II aGVHD resolved with steroids, none cGVHD, and 2 pro-
gressed. After a median follow-up of 6 months, all pts are alive and
6 in remission. Infections were notably lower than previously re-
ported by us with TCD HaploSCT. Day-100 TRM and NRM at
6 months were both 0%, remarkable as compared with our previ-
ous experience with TCD HaploSCT which showed that approxi-
mately 50% the pts would have expired by 6 months post-
transplant. Overall survival at 8 months was 39% in the TCD
group (N5 28) as compared with 100% in the TCR group
(N5 8) (p5 0.03).
Conclusion: Although limited by the small number of patients,
TCR HaploSCT using FMT and HDPTCy appears a safer
approach to HaploSCT and yielded remarkable early results with
successful engraftment and zero TRM and NRM in all treated pts.
A protocol has been open for patient accrual at our institution.164
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Sensitization to HLA antigens is an important consideration in
solid organ transplantation. Most data regarding the importance
of donor-specific antibodies (DSA) is derived from renal trans-
plants, where sensitization is clearly associated with an increased
risk of early graft loss. Therapy is directed at removal or reduction
of these antibodies and improved survival. The role of antibodies
in hematopoietic stem cell transplantation is less clear. Some stud-
ies suggest that anti-HLA antibodies are not significant unless
they are donor-specific. We describe the clinical outcome of
two patients, one with high titers of non-DSA and the other pos-
itive for DSA. Antibodies were determined using single HLA an-
tigens by solid-phase Luminex method. Mean fluorescence
intensity (MFI)$ 1500 was defined as positive. High resolution
HLA typing was performed. Patient one is a 44 y/o Native Amer-
ican woman with AML-M6 who underwent a reduced intensity
unrelated donor transplant. She had a broad range of activity
against several HLA antigens but did not have DSA. She initially
received IVIG followed by rituximab and cyclophosphamide with
no response. She successfully engrafted and subsequently has de-
veloped grade 2 GVHD. Day 100 PRA (percent panel reactive an-
tibody) continued to be positive. Patient two was a 52 y/o white
woman with MDS who underwent a total of 3 successive umbilical
cord blood transplants (CBT). She had high titers of Class I and
II antibodies which reacted with all donors tested. Non-reactive
donors could not be found. Attempted immunosuppression was
carried out with several doses of IVIG without response. She
failed to engraft following each CBT attempt and died with mar-
row failure. Preliminary data (in press) suggested a 44% incidence
of pre-formed Class I antibodies in marrow graft recipients. The
importance of non-DSA and/or minor histocompatibility sensiti-
zation in marrow graft rejection and GVHD remain to be clari-
fied. As described above, high titers of anti-HLA antibodies do
not preclude engraftment (patient 1) unless they are donor specific
(patient 2). The significance of DSA has been previously reported
by Takanashi et al. and is illustrated by the above cases. Treat-
ment of sensitization to donor specific antigens seems at present
to be unsatisfactory. Further studies will require an extensive
prospective data base to define relationships between clinical out-
come and approaches to therapy in sensitized marrow transplant
patients.
